DIAGENIC PARTNERS WITH DNAVision TO OFFER FIRST BREAST CANCER AND ALZHEIMER’S GENE-EXPRESSION BLOOD TESTS

OSLO. – November 28 2008 –DiaGenic ASA (OSL:DIAG) today announced that it has signed a service provider agreement with DNAVision, a leading panEuropean provider of gene expression-based diagnostic testing and services. With this laboratory service and following CE marking scheduled in early 2009, DiaGenic will be able to offer healthcare providers and patients in Europe its innovative blood-based gene-expression test for early detection of breast cancer and for Alzheimer’s disease in a CLIA/ISO17025 certified environment.


Joint press release from DNAVision and DiaGenic is enclosed.

Contact:

MD PhD Erik Christensen, CEO
Telephone: +47 95939918
e-mail: erik.christensen@diagenic.com

About Us

NEL ASA is a leading global supplier of hydrogen technology for industrial / energy purposes, and has made over 500 deliveries in more than 50 countries. The company's main products are hydrogen production plants based on water electrolysis, complete hydrogen stations for transport and renewable energy storage solutions. The company has its roots from the hydrogen activities of Norsk Hydro, which dates back to 1927. The company also has a number of patents related to tests for early detection and diagnosis of diseases.

Subscribe

Documents & Links